BMC Infectious Diseases
|
Viewing options:Associated material:Related literature:- Articles citing this article
- Other articles by authors
- Related articles/pages
Tools:Post to:
|
Technical advanceAn improved microtiter assay for evaluating anti-HIV-1 neutralizing antibodies from sera or plasmaChiyu Zhang1,2 , Yunyun Chen1 and Kunlong Ben1,3  1
Laboratory for Molecular and Cell Immunology, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan 650223, China 2
The School of Medical Technology, Jiangsu University, Zhenjiang, Jiangsu 212001, China 3
Kunming Chinawave Biotechnology Company Ltd., Kunming, Yunnan 650106, China author email corresponding author email
BMC Infectious Diseases 2003,
3:30doi:10.1186/1471-2334-3-30
|
|
| Published: |
23 December 2003 |
Abstract
Background
The anti-HIV-1 neutralizing antibody assay is widely used in AIDS vaccine research and other experimental and clinical studies. The vital dye staining method applied in the detection of anti-HIV-1 neutralizing antibody has been used in many laboratories. However, the unknown factor(s) in sera or plasma affected cell growth and caused protection when the tested sera or plasma was continuously maintained in cell culture. In addition, the poor solubility of neutral red in medium (such as RPMI-1640) also limited the use of this assay.
Methods
In this study, human T cell line C8166 was used as host cells, and 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) instead of neutral red was used as vital dye. In order to avoid the effect of the unknown factor(s), the tested sera or plasma was removed by a washout procedure after initial 3–6 h culture in the assay.
Result
This new assay eliminated the effect of the tested sera or plasma on cell growth, improved the reliability of detection of anti-HIV-1 neutralizing antibody, and showed excellent agreement with the p24 antigen method.
Conclusion
The results suggest that the improved assay is relatively simple, highly duplicable, cost-effective, and well reliable for evaluating anti-HIV-1 neutralizing antibodies from sera or plasma. |